Home

Analysis of matrix metallopeptidase 9 (MMP-9), tissue inhibitor of metalloproteinases type 1 (TIMP-1) and MMP‑9/TIMP‑1 complex in patients with acute myocardial infarction after percutaneous coronary interventions

Written by Grachev N.I., Krasnikov V.E., Turmova E.P., Markelova E.V., Rublev V.Yu, Nazarenko S.A.

  UDK: 616–005.8–089.819.843–089.168.1–06:616.153.96 | Pages: 45–48 | Full text PDF | Open PDF 

Annotation:

Objective. The objective of the study was to identify additional markers of complications of percutaneous coronary interventions in patients with acute myocardial infarction
Methods. We analyzed the serum content MMP-9, TIMP-1, and MMP- 9/TIMP-1 complex in 86 patients aged 41–74 with acute myocardial infarction before and after percutaneous coronary intervention.
Results. The serum levels of MMP-9 and TIMP-1 in patients with acute myocardial infarction are significantly higher than in healthy individuals, while the MMP-9/TIMP-1 complex, in contrast, is lower than in the control group. The dynamics of serum concentration of MMP-9 and TIMP-1 after the intervention had a different picture: by the 7th day, the level of MMP-9 increased, while the TIMP-1 values, on the contrary, decreased.
Conclusions. Our study proved the possibility of using the serum concentration of MMP-9 (426.8–978.4 ng/ml) as a predictor of early postoperative complications in patients with acute myocardial infarction after percutaneous coronary interventions.

Links to authors:

N.I. Grachev1, V.E. Krasnikov1, E.P. Turmova1, E.V. Markelova1, V.Yu. Rublev2, S.A. Nazarenko1
1 Pacific State Medical University (2 Ostryakova Ave. Vladivostok 690002 Russian Federation),
2 Primorye Regional Clinical Hospital No. 1 (57 Aleutskaya St. Vladivostok 690091 Russian Federation)


1. Akhmedov V.A., Dolgikh V.T., Naumov D.V., Nechiporenko N.A. The clinical significance of matrix metalloproteases in heart and vascular pathology // Pathological Physiology and Experimental Therapy. 2013. No. 2. P. 77–79.
2. Govorin A., Ratsina E., Sokolova N. Changes in matrix metalloproteinases and their tissue inhibitors in different forms of ischemic heart disease // Siberian Medical Journal (Irkutsk). 2014. Vol. 124, No. 1. P. 27–32.
3.Pecherina T.B., Gruzdeva O.V., Kashtalap V.V., Barbarash O.L. The role of matrix metalloproteinases in assessment of prognosis in patients with ST-elevation myocardial infarction during hospital stay // Kardiologiia. 2013. Vol. 53, No. 6. P. 18–24.
4. Ponomar’ E.G., Syrkin A.L., Gusev D.E., Andreev D.A. Inflammation markers and long-term prognosis in patients with acute coronary syndrome and stable coronary heart disease // Cardiology and Cardiovascular Surgery. 2011. Vol. 4, No. 6. P. 10–15.
5. Endovascular surgery: National Manual. Vol. 2. Ischemic heart disease / ed. by B.G. Aleksyan. Moscow: Litterra, 2017. 792 p.
6. Рогова Л.Н., Шестернина Н.В., Замечник Т.В., Фастова И.А. Матриксные металлопротеиназы, их роль в физиологических и патологических процессах // Вестник новых медицинских технологий. 2011. Т. 18, № 2. С. 86–89. Rogova L.N., Shesternina N.V., Zamechnik T.V., Fastova I.A. Matrix metalloproteinases, their role in physiological and pathological processes // Journal of New Medical Technologies. 2011. Vol. 18, No. 2. P. 86–89.
7. Силаев А.А., Турмова Е.П., Маркелова Е.В. [и др.]. Анализ эффективности цитокинотерапии в послеоперационном периоде у пациентов с коронарным атеросклерозом // Тихоокеанский медицинский журнал. 2013. № 3. С. 18–21. Silaev A.A., Turmova E.P., Markelova E.V. [et al.]. Assessing efficiency of cytokine therapy during post-operative period in patients with coronary atherosclerosis // Pacific Medical Journal. 2013. No. 3. P. 18–21.
8. Bigg H.F., Rowan A.D., Barker M.D., Cawston T.E. Activity of matrix metalloproteinase-9 against native collagen types I and III // FEBS J. 2007. Vol. 274. No. 5. P. 1246–1255.
9. Dinh W., Scheffold T., Bansemir L. [et al.]. Increased serum levels of tissue inhibitor of metalloproteinase-1 in patients with acute myocardial infarction // International Heart Journal. 2009. Vol. 50. No. 4. P. 421–431.
10. Furenes E.B., Opstad T.B., Solheim S. [et al.]. The influence of autologous bone marrow stem cell transplantation on matrix metalloproteinases in patients treated for acute ST-elevation myocardial infarction // Mediators Inflamm. 2014. doi: 10.1155/2014/385901.
11. Jefferis B.J., Whincup P., Welsh P. [et al.]. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women // Atherosclerosis. 2010. Vol. 208, No. 2. P. 557–563.
12. Opstad T.B, Arnesen H., Pettersen A.A. [et al.]. The MMP-9-1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease // PLoS One. 2014. Vol 9, No. 9. P. e106816.
13. Phatharajaree W., Phrommintikul A., Chattipakorn N. Matrix metalloproteinases and myocardial infarction // Can. J. Cardiol. 2007. Vol. 23, No. 9. P. 727–733.
14. Wang Y., Fu R., Wang Z. [et al.]. Assessing the quality of care for patients with acute myocardial infarction in China // Clin. Cardiol. 2015. Vol. 38, No. 6. P. 327–332.

PUBLISHER: "MEDITSYNA DV"

Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.